Fianlimab (REGN3767, anti-LAG3) is being tested in combination with cemiplimab (anti-PD-1) in a phase I dose-escalation study (NCT03005782) in advanced melanoma patients and showed clinical activities (217). Here, LAG3 is linked to melanoma.